- Brief report
- Open Access
Treatment of Acanthamoeba neurotrophic corneal ulcer with topical matrix therapy
© Mateo et al. 2015
- Received: 21 March 2015
- Accepted: 27 May 2015
- Published: 21 June 2015
This study was done to evaluate the visual and anatomical outcomes of topical regenerating agents as a novel therapy for neutrophic corneal ulcer (NCU) secondary to acanthamoeba infection.
A 20-year-old woman with a history of contact lens wear was referred to our hospital for keratitis after responding poorly to conventional treatment. In vivo confocal microscopy images suggested acanthamoeba keratitis with double-walled cysts in the anterior corneal stroma. Acanthamoeba infection was confirmed by laboratory findings. She was started on 0.1 % propamidine and 0.02 % chlorhexidine drops every hour. The antibiotic and antifungal drops were stopped when bacterial and fungal cultures proved negative. A central neurotrophic corneal ulcers (NCU) appeared, and despite treatment with artificial tears, bandage contact lens, and autologous serum, the ulcer worsened and she was treated with topical CACICOL20 (1 drop every 2 days) for 8 weeks. The corneal defect was completely repaired in 3 weeks. The treatment was well tolerated, and no local or systemic side effects were noted. Visual acuity remained 20/400. Two months later, the defect was still closed and the patient continued with 0.1 % propamidine and 0.02 % chlorhexidine drops, bandage contact lens, artificial tears, and autologous serum.
Topical regenerating agents interact with components of the extracellular matrix, binding matrix proteins and protecting them from proteolysis, restoring the matrix environment, and improving tissue healing. In this case, CALCICOL20 was effective for vision stabilization, wound healing, and was well tolerated for NCU secondary to acanthamoeba infection.
- Corneal neurotrophic ulcer
Neurotrophic corneal ulcers (NCU) are caused by different ocular and systemic conditions, such as diabetes, herpetic keratitis, corneal dystrophies, and chemical burns. These pathologies have in common a loss of corneal sensitivity leading to impaired healing . The management of NCU is difficult, and one of the most challenging conditions is caused by acanthamoeba infection. This parasite infection is a significant cause of ocular morbidity, but with early and aggressive treatment, acanthamoeba organisms may be eradicated. In some cases, severe inflammation, nerve affectation and necrosis, and substantial loss of corneal tissue may result, requiring more aggressive treatments, such as amniotic membrane transplantation (AMT) or penetrating keratoplasty (PK) .
A new approach for the treatment of NCU is topical regenerating agents (RGTA). When artificial tears, autologous serum, or bandage contact lenses fail, RGTA can be used before trying more aggressive treatments. RGTA comprise biopolymers engineered to mimic the structural and functional properties of heparan sulfates. RGTA interact with major components of the extracellular matrix, facilitating corneal healing and protecting against extensive proteolysis caused by the enzymatic activity that characterizes inflammatory, necrotic, or fibrotic sites . We present a case with NCU caused by acanthamoeba infection that was treated successfully with the RGTA, CACICOL20.
Trophic ulcerations result from abnormal repair of the corneal epithelium. Management of this type of ulceration is very challenging. Classical treatment includes lubrication with unpreserved artificial teardrops and topical ointment with patching. If this treatment is not effective, autologous serum and topical growth factors can be used. More aggressive treatment includes temporary or permanent tarsorrhaphy, conjunctival flaps, AMT, and lamellar or PK. A new treatment approach for this type of ulcer is matrix RGTA, such as CACICOL20 (RGTA dextran and poly/carboxymethylglucose sulfate). RGTA are biopolymers engineered to replace the components involved in wound healing . CACICOL20 interacts with components of the extracellular matrix, binding matrix proteins, protecting them from proteolysis, restoring the matrix environment, and improving tissue healing.
CACICOL20 is successfully used to treat corneal dystrophies as well as corneal ulcers resistant to standard treatment. Chebbi et al.  presented 11 cases with severe corneal dystrophies and painful corneal ulcers with good results in healing. De Monchy et al.  reported a case of neurotrophic herpes ulcer successfully treated in 3 weeks with topical RGTA. Kymionis et al.  described three cases, including neurotrophic keratopathy, corneal dystrophy, and PK with persistent epithelial defects, that were treated with RGTA, and the epithelial defects were closed in less than 3 weeks. Brignole-Baudouin et al.  investigated the effect of RGTA-OTR4120 in an alkali-burned rabbit corneal model and demonstrated that RGTA is well tolerated, and RGTA-treated eyes have fewer signs of inflammation and better reepithelialization. Cejkove et al.  also reported a good response in an alkali-burned rabbit corneal model treated with CACICOL20.
To our knowledge, this is the first case of NCU caused by acanthamoeba infection that was successfully treated with CACICOL20. Aifa et al.  treated 11 cases of NCU with topical RGTA. They reported that eight cases successfully responded to the treatment, but the other three cases did not show a good response, including a case of acanthamoeba keratitis. This lack of response is contrary to our case.
Hick et al.  presented 33 cases of NCU resistant to conventional treatment using AMT; failure was noted in six eyes, one of which had an NCU due to acanthamoeba infection. Acanthamoeba keratitis can be severe and difficult to treat, leading to corneal thinning and risk of perforation, and sometimes requiring PK.
We present a case in which an NCU caused by complications of acanthamoeba infection was successfully treated with CACICOL20. This RGTA could be effective for ulcers resistant to other treatments. This promising drug demonstrates good efficacy and is well tolerated. Further studies are needed, however, to confirm these excellent results.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
Funding/support: no funding was needed for this work or this manuscript.
The manuscript has been edited by professional native English-speaking science editors (SciTechEdit International; http://www.scitechedit.com).
- Sacchetti M, Lambiase A (2014) Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol 8:571–579PubMed CentralPubMedGoogle Scholar
- Graffi S, Peretz A, Jabaly H, Naftali M (2013) Acanthamoeba keratitis. Isr Med Assoc J 15(4):182–5PubMedGoogle Scholar
- Barbier-Chassefière V, Garcia-Filipe S, Yue XL et al (2009) Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J Biomed Mater Res A 90(3):641–7PubMedView ArticleGoogle Scholar
- Chebbi CK, Kichenin K, Amar N et al (2008) Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy. J Fr Ophtalmol 31(5):465–71PubMedView ArticleGoogle Scholar
- De Monchy I, Labbé A, Pogorzalek N et al (2012) Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): a case report. J Fr Ophtalmol 35(3):187.e1-6PubMedView ArticleGoogle Scholar
- Kymionis GD, Liakopoulos DA, Grentzelos MA et al (2014) Combined topical application of a regenerative agent with a bandage contact lens for the treatment of persistent epithelial defects. Cornea 33(8):868–72PubMedView ArticleGoogle Scholar
- Brignole-Baudouin F, Warnet JM, Barritault D, Baudouin C (2013) RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies. J Fr Ophtalmol 36(9):740–7PubMedView ArticleGoogle Scholar
- Cejkova J, Olmiere C, Cejka C, Trosan P, Holan V (2014) The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage. Histol Histopathol 29(4):457–78PubMedGoogle Scholar
- Aifa A, Gueudry J, Portmann A, Delcampe A, Muraine M (2012) Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest Ophthalmol Vis Sci 53(13):8181–5PubMedView ArticleGoogle Scholar
- Hick S, Demers PE, Brunette I, La C, Mabon M, Duchesne B (2005) Amniotic membrane transplantation and fibrin glue in the management of corneal ulcers and perforations: a review of 33 cases. Cornea 24(4):369–77PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.